Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells

Ramadevi Nimmanapalli, Purva Bali, Erica O'Bryan, Lianne Fuino, Fei Guo, Jie Wu, Peter J Houghton, Kapil Bhalla

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Present studies demonstrate that treatment with arsenic trioxide (AT) lowered ectopically expressed or endogenous levels of Bcr-Abl protein, as well as induced apoptosis of Bcr-Abl-expressing cultured and primary chronic myeloid leukemia cells, including those refractory to imatinib mesylate. Treatment with AT neither affected bcr-abl mRNA transcript levels nor promoted the proteasomal degradation of Bcr-Abl. Importantly, in [35S]methionine-labeled leukemia cells, exposure to AT rapidly lowered the levels of the newly synthesized Bcr-Abl, indicating inhibition of bcr-abl mRNA translation. Treatment with AT rapidly inhibited the activity of 3-phosphoinositide-dependent protein kinase-1, as well as of p70 S6 kinase-1. p70 S6 kinase-1 is known to be a positive regulator of the translation of a group of mRNAs that possesses a long and highly structured 5′ -untranslated region (UTR) containing a tract of oligopyrimidines (TOP). Because bcr-abl mRNA was discovered to possess a long and highly structured 5′-UTR containing a 12-pyrimidine TOP sequence in its 5′-UTR, we determined the effect of AT in Jurkat cells with ectopic expression of a 5′-UTR-deleted mutant of the bcr-abl gene, i.e., Jurkat/Bcr-Abl (5′UTR-) cells. Treatment with AT neither lowered the levels of the 5′-UTR-deleted mutant of Bcr-Abl nor induced apoptosis of Jurkat/Bcr-Abl (5′UTR-) cells. Taken together, these findings demonstrate a novel mechanism by which AT down-regulates Bcr-Abl levels and induces apoptosis of Bcr-Abl-positive chronic myelogenous leukemia cells.

Original languageEnglish (US)
Pages (from-to)7950-7958
Number of pages9
JournalCancer Research
Volume63
Issue number22
StatePublished - Nov 15 2003
Externally publishedYes

Fingerprint

Protein Biosynthesis
Leukemia
5' Untranslated Regions
Apoptosis
70-kDa Ribosomal Protein S6 Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Messenger RNA
3-Phosphoinositide-Dependent Protein Kinases
abl Genes
Jurkat Cells
Myeloid Cells
arsenic trioxide
Methionine
Down-Regulation
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nimmanapalli, R., Bali, P., O'Bryan, E., Fuino, L., Guo, F., Wu, J., ... Bhalla, K. (2003). Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells. Cancer Research, 63(22), 7950-7958.

Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells. / Nimmanapalli, Ramadevi; Bali, Purva; O'Bryan, Erica; Fuino, Lianne; Guo, Fei; Wu, Jie; Houghton, Peter J; Bhalla, Kapil.

In: Cancer Research, Vol. 63, No. 22, 15.11.2003, p. 7950-7958.

Research output: Contribution to journalArticle

Nimmanapalli, R, Bali, P, O'Bryan, E, Fuino, L, Guo, F, Wu, J, Houghton, PJ & Bhalla, K 2003, 'Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells', Cancer Research, vol. 63, no. 22, pp. 7950-7958.
Nimmanapalli, Ramadevi ; Bali, Purva ; O'Bryan, Erica ; Fuino, Lianne ; Guo, Fei ; Wu, Jie ; Houghton, Peter J ; Bhalla, Kapil. / Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells. In: Cancer Research. 2003 ; Vol. 63, No. 22. pp. 7950-7958.
@article{a5b3a2e8f1f24a17a988ed805aa91c15,
title = "Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells",
abstract = "Present studies demonstrate that treatment with arsenic trioxide (AT) lowered ectopically expressed or endogenous levels of Bcr-Abl protein, as well as induced apoptosis of Bcr-Abl-expressing cultured and primary chronic myeloid leukemia cells, including those refractory to imatinib mesylate. Treatment with AT neither affected bcr-abl mRNA transcript levels nor promoted the proteasomal degradation of Bcr-Abl. Importantly, in [35S]methionine-labeled leukemia cells, exposure to AT rapidly lowered the levels of the newly synthesized Bcr-Abl, indicating inhibition of bcr-abl mRNA translation. Treatment with AT rapidly inhibited the activity of 3-phosphoinositide-dependent protein kinase-1, as well as of p70 S6 kinase-1. p70 S6 kinase-1 is known to be a positive regulator of the translation of a group of mRNAs that possesses a long and highly structured 5′ -untranslated region (UTR) containing a tract of oligopyrimidines (TOP). Because bcr-abl mRNA was discovered to possess a long and highly structured 5′-UTR containing a 12-pyrimidine TOP sequence in its 5′-UTR, we determined the effect of AT in Jurkat cells with ectopic expression of a 5′-UTR-deleted mutant of the bcr-abl gene, i.e., Jurkat/Bcr-Abl (5′UTR-) cells. Treatment with AT neither lowered the levels of the 5′-UTR-deleted mutant of Bcr-Abl nor induced apoptosis of Jurkat/Bcr-Abl (5′UTR-) cells. Taken together, these findings demonstrate a novel mechanism by which AT down-regulates Bcr-Abl levels and induces apoptosis of Bcr-Abl-positive chronic myelogenous leukemia cells.",
author = "Ramadevi Nimmanapalli and Purva Bali and Erica O'Bryan and Lianne Fuino and Fei Guo and Jie Wu and Houghton, {Peter J} and Kapil Bhalla",
year = "2003",
month = "11",
day = "15",
language = "English (US)",
volume = "63",
pages = "7950--7958",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells

AU - Nimmanapalli, Ramadevi

AU - Bali, Purva

AU - O'Bryan, Erica

AU - Fuino, Lianne

AU - Guo, Fei

AU - Wu, Jie

AU - Houghton, Peter J

AU - Bhalla, Kapil

PY - 2003/11/15

Y1 - 2003/11/15

N2 - Present studies demonstrate that treatment with arsenic trioxide (AT) lowered ectopically expressed or endogenous levels of Bcr-Abl protein, as well as induced apoptosis of Bcr-Abl-expressing cultured and primary chronic myeloid leukemia cells, including those refractory to imatinib mesylate. Treatment with AT neither affected bcr-abl mRNA transcript levels nor promoted the proteasomal degradation of Bcr-Abl. Importantly, in [35S]methionine-labeled leukemia cells, exposure to AT rapidly lowered the levels of the newly synthesized Bcr-Abl, indicating inhibition of bcr-abl mRNA translation. Treatment with AT rapidly inhibited the activity of 3-phosphoinositide-dependent protein kinase-1, as well as of p70 S6 kinase-1. p70 S6 kinase-1 is known to be a positive regulator of the translation of a group of mRNAs that possesses a long and highly structured 5′ -untranslated region (UTR) containing a tract of oligopyrimidines (TOP). Because bcr-abl mRNA was discovered to possess a long and highly structured 5′-UTR containing a 12-pyrimidine TOP sequence in its 5′-UTR, we determined the effect of AT in Jurkat cells with ectopic expression of a 5′-UTR-deleted mutant of the bcr-abl gene, i.e., Jurkat/Bcr-Abl (5′UTR-) cells. Treatment with AT neither lowered the levels of the 5′-UTR-deleted mutant of Bcr-Abl nor induced apoptosis of Jurkat/Bcr-Abl (5′UTR-) cells. Taken together, these findings demonstrate a novel mechanism by which AT down-regulates Bcr-Abl levels and induces apoptosis of Bcr-Abl-positive chronic myelogenous leukemia cells.

AB - Present studies demonstrate that treatment with arsenic trioxide (AT) lowered ectopically expressed or endogenous levels of Bcr-Abl protein, as well as induced apoptosis of Bcr-Abl-expressing cultured and primary chronic myeloid leukemia cells, including those refractory to imatinib mesylate. Treatment with AT neither affected bcr-abl mRNA transcript levels nor promoted the proteasomal degradation of Bcr-Abl. Importantly, in [35S]methionine-labeled leukemia cells, exposure to AT rapidly lowered the levels of the newly synthesized Bcr-Abl, indicating inhibition of bcr-abl mRNA translation. Treatment with AT rapidly inhibited the activity of 3-phosphoinositide-dependent protein kinase-1, as well as of p70 S6 kinase-1. p70 S6 kinase-1 is known to be a positive regulator of the translation of a group of mRNAs that possesses a long and highly structured 5′ -untranslated region (UTR) containing a tract of oligopyrimidines (TOP). Because bcr-abl mRNA was discovered to possess a long and highly structured 5′-UTR containing a 12-pyrimidine TOP sequence in its 5′-UTR, we determined the effect of AT in Jurkat cells with ectopic expression of a 5′-UTR-deleted mutant of the bcr-abl gene, i.e., Jurkat/Bcr-Abl (5′UTR-) cells. Treatment with AT neither lowered the levels of the 5′-UTR-deleted mutant of Bcr-Abl nor induced apoptosis of Jurkat/Bcr-Abl (5′UTR-) cells. Taken together, these findings demonstrate a novel mechanism by which AT down-regulates Bcr-Abl levels and induces apoptosis of Bcr-Abl-positive chronic myelogenous leukemia cells.

UR - http://www.scopus.com/inward/record.url?scp=0344844465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344844465&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 7950

EP - 7958

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 22

ER -